Vanguard Asset Management
MYGN icon

Vanguard Asset Management’s Myriad Genetics MYGN Stock Holding History

Vanguard Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Sell
4,137
-52,080
-93% -$236K ﹤0.01% 2427
2026
Q1 		$253K Buy
+56,217
New +$293K ﹤0.01% 2324

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Asset Management's MYGN Position: Q2 2026 in Review

Vanguard Asset Management reduced its Myriad Genetics (MYGN) stake by 93% in Q2 2026, selling an estimated $236K and leaving 4,137 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2427.

Vanguard Asset Management first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $253K in Q1 2026. 183 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Vanguard Asset Management held 4,137 shares of Myriad Genetics worth $23.6K as of Q2 2026.
  • Vanguard Asset Management sold 52,080 Myriad Genetics shares in Q2 2026, an estimated $236K.
  • Myriad Genetics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2427 holding.
  • Vanguard Asset Management first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Myriad Genetics position peaked at $253K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.